AVITA Medical (AVHHL) Cost of Revenue (2018 - 2026)

AVITA Medical (AVHHL) has reported Cost of Revenue for 9 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 13.43% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $13.9 million (up 18.03% YoY), and the FY2025 full-year result was $12.8 million, up 40.69% from the prior year.
• Cost of Revenue advanced to $3.9 million in Q2 2026 per AVHHL's latest filing, from $3.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.9 million in Q2 2026 and bottomed at $1.5 million in Q1 2024.
• Historically, Cost of Revenue has averaged $2.4 million across 5 years, with a median of $2.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue slumped 71.06% in 2022, then jumped 87.24% in 2025.
• Over 5 years, Cost of Revenue stood at $2.1 million in 2022, then retreated by 13.49% to $1.8 million in 2023, then gained by 26.95% to $2.3 million in 2024, then surged by 44.91% to $3.3 million in 2025, then rose by 19.1% to $3.9 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.9 million, $3.3 million, and $3.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.